Vaxart, Inc. (VXRT): Nasdaq/NYSE listing notice — Vaxart receives Nasdaq delisting notice after withdrawing reverse stock split

Vaxart, Inc.

On Sept 19, 2025, Nasdaq notified Vaxart that its securities will be delisted due to noncompliance with the Panel's conditions.
The company withdrew its reverse stock split proposal on Sept 18, 2025, failing a key condition for continued listing.
Trading on Nasdaq was suspended since July 8, 2025; VXRT now trades on OTCQX Best Market.
The Panel had required shareholder approval of a reverse split by Sept 5, 2025, and completion by Oct 6, 2025.
No further Nasdaq listing appeal is indicated; stock continues trading OTC under symbol VXRT.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vaxart, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

September 19, 2025, the Company received a letter from the Office of the General Counsel of Nasdaq, stating that the Company’s securities will be delisted from Nasdaq as a result of the Company’s noncompliance with the Panel’s Conditions. Trading in the Company’s common stock on Nasdaq was suspended at the open of trading on July 8, 2025. The Company’s common stock is currently quoted on the OTCQX® Best Market under the symbol “VXRT.” SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unde

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-029485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.